2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C

Clin Mol Hepatol. 2018 Sep;24(3):169-229. doi: 10.3350/cmh.2018.1004. Epub 2018 Aug 10.
No abstract available

Keywords: Chronic hepatitis C; Direct acting antivirals; Guidelines; Treatment.

Publication types

  • Practice Guideline
  • Review

MeSH terms

  • Benzimidazoles / adverse effects
  • Benzimidazoles / metabolism
  • Benzimidazoles / therapeutic use
  • Carbamates
  • Dose-Response Relationship, Drug
  • Drug Interactions
  • Fluorenes / adverse effects
  • Fluorenes / metabolism
  • Fluorenes / therapeutic use
  • Hepatitis C, Chronic / drug therapy*
  • Humans
  • Imidazoles / adverse effects
  • Imidazoles / metabolism
  • Imidazoles / therapeutic use
  • Isoquinolines / adverse effects
  • Isoquinolines / metabolism
  • Isoquinolines / therapeutic use
  • Kidney / drug effects
  • Kidney / physiology
  • Protease Inhibitors / adverse effects
  • Protease Inhibitors / metabolism
  • Protease Inhibitors / therapeutic use*
  • Pyrrolidines
  • Sofosbuvir / adverse effects
  • Sofosbuvir / metabolism
  • Sofosbuvir / therapeutic use
  • Sulfonamides / adverse effects
  • Sulfonamides / metabolism
  • Sulfonamides / therapeutic use
  • Valine / analogs & derivatives

Substances

  • Benzimidazoles
  • Carbamates
  • Fluorenes
  • Imidazoles
  • Isoquinolines
  • Protease Inhibitors
  • Pyrrolidines
  • Sulfonamides
  • ledipasvir
  • Valine
  • daclatasvir
  • asunaprevir
  • Sofosbuvir